This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Exploring the Impact of Dupixent's FDA Approval for Chronic Spontaneous Urticaria
Ticker(s): SNY, REGNWho's the expert?
Institution: Institute For Asthma & Allergy
- Director of the Center for Urticaria and Angioedema at the Institute For Asthma & Allergy.
- Manages ~400 pateints for urticaria annually.
- Also maintains a part-time faculty position at the Johns Hopkins.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
